Evidence map›Paper›PMID 40666772›Full record

ArticleOman journal of ophthalmology

Corneal melting following intrastromal injection of bevacizumab for corneal neovascularization.

Muna Salim Al-Ruhaili, Haitham Hilal Al-Mahrouqi

Abstract readCase Reports
In one paragraph

Article in Oman journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Muna Salim Al-RuhailiOphthalmology Residency Program, Oman Medical Specialty Board, Muscat, Sultanate of Oman.
Haitham Hilal Al-MahrouqiDepartment of Ophthalmology, Al-Nahdha Hospital, Ministry of Health, Muscat, Sultanate of Oman.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim is to report corneal melting following intrastromal injection of antivascular endothelial growth factor (anti-VEGF), bevacizumab, for pre-existing corneal neovascularization. A 68-year-old male with a history of failed bilateral penetrating keratoplasties due to scarring from childhood measles and trachoma underwent right eye superficial keratectomy, intrastromal bevacizumab, and amniotic membrane transplant to control the neovascularization in an overseas center. A week later developed corneal melting. In conclusion, anti-VEGF can be used in controlling corneal neovascularization, albeit, is associated with risks such as delayed epithelial healing and corneal melting, particularly in those with limbal stem cell deficiency.

Indexed as

Anti-vascular endothelial growth factorcorneal graft failurecorneal meltingcorneal neovascularizationgraft rejectionintrastromal anti-vascular endothelial growth factorintrastromal bevacizumab

Identifiers

PMID40666772
PMCPMC12258859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.